A ‘significant shift’ is under way in global outsourcing strategies: with the sector moving away from phase-appropriate development in favor of a more forward-looking model – with experts advising starting the search for an outsourcing partner as early...
Catalent has announced a multi-year $350m investment at its facility in Bloomington, Indiana, to expand biologics drug substance and drug product manufacturing capabilities.
The World Health Organization has recommended the drugs for COVID-19 patients, broadening the range of therapies to combat the virus behind the pandemic.
According to the pharma firm, Saphnelo (anifrolumab) combined with standard therapy resulted in reduction of systemic lupus erythematosus disease activity.
The US Food and Drug Administration has kept its staff busy with approvals, authorizations, and warnings related to various coronavirus-centered products.
Organicell has announced the initial results from its India-based trial of the COVID-19 treatment Zofin look promising, plans to expand to more patients.
Eversana adopts Cryoport’s full suite of logistics services, in an alliance expected to ‘drive synergistic growth’ for both companies and answer regenerative medicine demands.
SGS’ completed the ₤8.7m expansion of its large molecule testing facility in Glasgow and made room to increase its existing biosafety service and PCR platform capabilities.
I-Mab and WuXi Biologics extend their strategic partnership for biologics process development as well as clinical and commercial manufacturing to accelerate drug development in China and abroad.
Twist Bioscience, a synthetic DNA provider, enters a strategic collaboration with LakePharma to bolster antibody discovery and optimization for biologic drug development.
The US-based CDMO Cognate intends to collaborate with Astero to provide access to the latter’s cell thawing platform to improve product quality in clinical manufacturing and establish a center of innovation.
Thousand Oaks Biopharmaceuticals raised $45m in Series A financing, enabling the company to expand its CDMO and CMC services as well as its capabilities in global biologics development.
Eli Lilly and Company and AC Immune have signed an agreement for the research and development of tau aggregation inhibitor small molecules, and AC Immune signed a strategic partnership with WuXi biologics.
This second phase of the two-phase expansion project will increase the company’s bioanalytical capabilities at the site by 50% when the expansion is complete in 2020.
PPD is adding nearly 6,000 square feet of new lab space – and about 20 employees – dedicated to gene and cell therapy analytical testing at its site in Athlone, Ireland.
The biopharmaceutical analytical and bioanalytical contract solutions provider SGS is investing more than $1.7m to expand its North American biopharmaceutical testing capabilities.
